ATE493652T1 - Quantitative assays für pdgfr-beta- in körperflüssigkeiten - Google Patents

Quantitative assays für pdgfr-beta- in körperflüssigkeiten

Info

Publication number
ATE493652T1
ATE493652T1 AT06801170T AT06801170T ATE493652T1 AT E493652 T1 ATE493652 T1 AT E493652T1 AT 06801170 T AT06801170 T AT 06801170T AT 06801170 T AT06801170 T AT 06801170T AT E493652 T1 ATE493652 T1 AT E493652T1
Authority
AT
Austria
Prior art keywords
beta
diseases
body fluid
patient
monitor
Prior art date
Application number
AT06801170T
Other languages
English (en)
Inventor
Peter Hamer
Walter Carney
Leticia Morris
James Elting
Original Assignee
Siemens Healthcare Diagnostics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Healthcare Diagnostics filed Critical Siemens Healthcare Diagnostics
Application granted granted Critical
Publication of ATE493652T1 publication Critical patent/ATE493652T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/49—Platelet-derived growth factor [PDGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT06801170T 2005-08-11 2006-08-10 Quantitative assays für pdgfr-beta- in körperflüssigkeiten ATE493652T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70780605P 2005-08-11 2005-08-11
PCT/US2006/031245 WO2007021860A2 (en) 2005-08-11 2006-08-10 QUANTITATIVE ASSAYS FOR PDGFR-β IN BODY FLUIDS

Publications (1)

Publication Number Publication Date
ATE493652T1 true ATE493652T1 (de) 2011-01-15

Family

ID=37758168

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06801170T ATE493652T1 (de) 2005-08-11 2006-08-10 Quantitative assays für pdgfr-beta- in körperflüssigkeiten

Country Status (5)

Country Link
US (1) US20070037224A1 (de)
EP (1) EP1913391B1 (de)
AT (1) ATE493652T1 (de)
DE (1) DE602006019262D1 (de)
WO (1) WO2007021860A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) * 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
JP4636486B2 (ja) * 2002-02-11 2011-02-23 バイエル、ファーマシューテイカルズ、コーポレイション 脈管形成阻害活性を有するアリール尿素
US7874293B2 (en) * 2003-02-21 2011-01-25 Resmed Limited Nasal assembly
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US7191068B2 (en) * 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
US8068990B2 (en) * 2003-03-25 2011-11-29 Hologic, Inc. Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids
PL1636585T3 (pl) * 2003-05-20 2008-10-31 Bayer Healthcare Llc Diarylowe pochodne mocznika inhibowane kinazą
KR20080073711A (ko) * 2005-10-21 2008-08-11 바이엘 헬스케어 엘엘씨 암의 예측 및 예후 방법, 및 암 치료 모니터링 방법
KR20170091174A (ko) * 2007-04-03 2017-08-08 옥시레인 유케이 리미티드 분자의 글리코실화
US20110124965A1 (en) * 2008-05-08 2011-05-26 Park Jason Y Chemiluminescence enhanced detection
EP2300825A4 (de) * 2008-06-18 2012-04-25 Abbott Lab P/gf-1-begleitdiagnostikverfahren und -produkte
US20100004306A1 (en) * 2008-06-18 2010-01-07 Abbott Laboratories PIGF-1 Assay and kits and components thereof
US8741287B2 (en) * 2008-06-18 2014-06-03 Abbott Laboratories PlGF-1 assay and kits and components thereof
DK2324111T3 (da) * 2008-09-10 2013-09-30 Life & Brain Gmbh Yderzone-tumorceller samt fremgangsmåde til fremstilling deraf samt anvendelse deraf
JP5612067B2 (ja) * 2009-03-19 2014-10-22 ユニバーシティ ダンガース 肝線維化進行を評価するための非侵襲的方法
CN102445543B (zh) * 2010-10-08 2014-03-12 中国医学科学院肿瘤研究所 辅助诊断肺癌***转移的试剂
GB201204014D0 (en) * 2012-03-07 2012-04-18 Univ Leeds Diagnostic marker compounds and their use
US9915660B2 (en) 2013-03-15 2018-03-13 Morphotek, Inc. Methods for determining prognosis of colorectal cancer
KR102200344B1 (ko) 2013-04-25 2021-01-11 씨비에스바이오사이언스 주식회사 간세포 종양에 있어서 분자-표적 치료의 감수성을 증가시키기 위한 분석방법
CA3032465A1 (en) 2016-08-01 2018-02-08 Centre Hospitalier Universitaire D'angers Multi-targeted fibrosis tests
WO2020099487A1 (en) * 2018-11-14 2020-05-22 Vrije Universiteit Brussel Soluble pdgfrbeta as a biomarker for fibrosis
KR102363980B1 (ko) * 2020-04-13 2022-02-15 전남대학교산학협력단 전이성 뇌종양의 진단 또는 예후 분석용 바이오마커 및 이를 이용한 진단방법
US20240132602A1 (en) * 2021-03-19 2024-04-25 Eli Lilly And Company Methods of treating cancer with pdgfr alpha inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4745181A (en) 1986-10-06 1988-05-17 Ciba Corning Diagnostics Corp. Polysubstituted aryl acridinium esters
US6372438B1 (en) * 1988-02-02 2002-04-16 The Regents Of The University Of California Human platelet-derived growth factor receptors
US6110737A (en) * 1988-02-02 2000-08-29 The Regents Of The University Of California Human platelet-derived growth factor receptor, type A
US5468468A (en) * 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
US6228600B1 (en) * 1992-07-20 2001-05-08 The United States Of America As Represented By The Department Of Health And Human Services Immunoassays for the alpha platelet-derived growth factor receptor
DE69034254D1 (de) * 1989-02-09 2008-07-17 Us Health A-pdgf-rezeptor und dessen verwendung
ATE109510T1 (de) * 1989-05-22 1994-08-15 Zymogenetics Inc Pdgf-alpha-rezeptor.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5395752A (en) 1993-03-19 1995-03-07 Ciba Corning Diagnostics Corp. Long emission wavelength chemiluminescent compounds and their use in test assays
US6264949B1 (en) * 1998-09-29 2001-07-24 Mount Sinai School Of Medicine Of New York University Noninvasive agents for diagnosis and prognosis of the progression of fibrosis
US7473534B2 (en) * 2002-03-01 2009-01-06 Siemens Healthcare Diagnostics Inc. Assays for cancer patient monitoring based on levels of epidermal growth factor receptor (EGFR) extracellular domain (ECD) analyte, alone or in combination with other analytes, in body fluid samples
PL1636585T3 (pl) * 2003-05-20 2008-10-31 Bayer Healthcare Llc Diarylowe pochodne mocznika inhibowane kinazą
WO2005015236A2 (en) * 2003-07-18 2005-02-17 Roche Diagnostics Gmbh A method for predicting the progression of adenocarcinoma

Also Published As

Publication number Publication date
DE602006019262D1 (de) 2011-02-10
WO2007021860A3 (en) 2007-10-04
EP1913391B1 (de) 2010-12-29
WO2007021860B1 (en) 2008-02-28
EP1913391A4 (de) 2009-02-18
US20070037224A1 (en) 2007-02-15
EP1913391A2 (de) 2008-04-23
WO2007021860A2 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
ATE493652T1 (de) Quantitative assays für pdgfr-beta- in körperflüssigkeiten
HK1183707A1 (en) Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease (pct)
DE602006018578D1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
JP2017215338A5 (de)
RU2017126701A (ru) Способ детекции нуклеосом, содержащих нуклеотиды
ATE456055T1 (de) Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden
DE602006007703D1 (de) Verbesserte immuntestverfahren
CY1113403T1 (el) Νεος βιοδεικτης για την παρακολουθηση της εξελιξης των νοσων και την εκτιμηση της αποτελεσματικοτητας των θεραπειων
RU2018101257A (ru) Способ детекции нуклеосом, содержащих гистоновые варианты
CN102292637A (zh) 用于检测或监测急性肾损伤的方法、装置和试剂盒
MX2009003562A (es) Ensayo elisa para la deteccion de vegf.
BRPI0509419A (pt) método de ensaio imunossorvente ligado por enzimas, anticorpos, hibridoma e kit de imunoensaio
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
WO2007080597A3 (en) Polynucleotide and polypeptide sequences and methods for diagnosis
WO2006113210A3 (en) Diagnostic multimarker serological profiling
O’Byrne et al. Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma
ATE476652T1 (de) Quantitative assays für ras p21 in körperflüssigkeiten
Dalirsani et al. Comparison of matrix metalloproteinases 2 and 9 levels in saliva and serum of patients with head and neck squamous cell carcinoma and healthy subjects
BRPI0610267B8 (pt) métodos de detecção de um estado doentio ou de uma suscetibilidade à doença em um indivíduo mamífero, e, uso do método
Kim et al. Indenter study: associations between prostate elasticity and lower urinary tract symptoms
WO2005065328A3 (en) Macrophage migration inhibitory factor (mif) as marker for urological inflammatory disease
Köhnke et al. Proposal for a novel scoring system for the diagnosis of CLL
RU2015124349A (ru) Способ дооперационного прогнозирования стадии и агрессивности рака предстательной железы
Chacko Matrix metalloproteinases
PL438042A1 (pl) Stężenie chromu w surowicy jako marker prognostyczny u chorych z rakiem piersi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties